Overview
Neutralizes myostatin and activins by binding directly to them, preventing ActRIIB receptor activation.
Proposed mechanism
Follistatin binds to myostatin (GDF-8) with high affinity, preventing myostatin from activating its receptor on muscle cells.
What the evidence supports
Evidence rests primarily on self-reported experience. Controlled studies are lacking.
Graded Anecdotal
Case reports, clinician notes, and user-reported outcomes. Recorded for completeness and labelled plainly so it is never mistaken for data.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
Follistatin and myostatin
· DOI:10.1016/S1097-2765(02)00717-9 · 2002
- [2]
Myostatin inhibition risks
· DOI:10.1016/j.cmet.2012.10.013 · 2012
- [3]
Follistatin and myostatin (2002)
· · 0
- [4]
Myostatin inhibition risks (2012)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.